Short-Term Debt to Capital: AngioDynamics Inc (ANGO)

Corporate company logo of AngioDynamics, Inc. (ANGO)

AngioDynamics, Inc. (ANGO) generates revenue through the sale of vascular therapy systems and oncology equipment. FDA certifications and patent protection ensure a high barrier to entry. The asset value of 0.02 shown on this chart reflects the financial dynamics. A team of top-tier engineers drives innovation here, receiving competitive benefits and long-term job security in return.

ANGO - AngioDynamics Inc Short-Term Debt to Capital Coefficient over the range 07/04/2022 - 10/30/2026

Analytical breakdowns for AngioDynamics, Inc.

- stock quotes and analyst forecast:
Stock Price AngioDynamics Corp|ANGO - Average Forecast Price
- company stock exchange capitalization indicators:
Market Capitalization AngioDynamics Inc|ANGO - Business Value
- book capitalization information:
Book Value per Share AngioDynamics|ANGO - Book Valuation of Business|Market Capitalization to Book Value Ratio angiodynamics.com|ANGO - Cumulative Company Assets
- business debt structure and liquidity details:
Total Debt to Capital AngioDynamics, Inc.|ANGO - Long-Term Debt to Capital|Short-Term Debt to Equity AngioDynamics|ANGO - Company Debts|Debt to Book Value AngioDynamics Inc|ANGO - Company Long-Term Loans and Borrowings|Company Short-Term Debts AngioDynamics|Quick Liquidity angiodynamics.com
- earnings and market ratios statistics:
ANGO - Company Profit
General company analysis:AngioDynamics Corp ANGO
Brand item of AngioDynamics

An optimal capital structure separates sustainable development from risky speculation. The strategic focus of AngioDynamics, Inc. (ANGO) on high-tech proprietary devices in vascular surgery strengthens its financial foundation. The dynamics of the short-term debt-to-equity ratio reflect the proportion of current loans to equity, revealing the dependency on short-term borrowings. Low values of this ratio confirm the business's protection against credit shocks and its high solvency.

Direct competitors

Short-Term Debt to Capital ISRG|DHR - Current Liabilities to Capital|Short-Term Debt to Capital BDX (Becton Dickinson & Co)|STE: Short-Term Debt to Capital Ratio|West Pharmaceutical Services, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient Baxter International Inc. BAX|MASI: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Stevanato Group Corp|TFX (Teleflex Incorporated) - Short-Term Debt to Capital|Short-Term Debt to Capital merit.com|Short-Term Debt to Equity Envista (NVST)|Short-Term Debt to Equity ICUI (ICU Medical Inc)|Dentsply - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital LMAT|AtriCure, Inc. - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient staar.com STAA|Niagen (NAGE) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio ZIMV|Short-Term Debt to Equity Cerus Corp|Teknova Inc (TKNO) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio MGRM (Monogram Technologies)|Short-Term Loans to Capital Ratio STSS|Short-Term Debt to Equity InfuSystem Holdings, Inc. INFU|Ratio of Short-Term Indebtedness to Capital UTMD|KRMD: Short-Term Debt to Equity Ratio|NYXH - Short-Term Debt to Capital|Microbot Medical Inc. (MBOT) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio pro-dex.com|ZTEK (Zentek) - Short-Term Debt to Capital|Current Liabilities to Capital Elutia Inc ELUT|Short-Term Debt to Equity Milestone Scientific Corp (MLSS)|NEXGEL Inc - Short-Term Debt to Capital Ratio|Retractable Technologies, Inc. - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio HBIO (Harvard Bioscience Inc.)|FEMY - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient MeihuaMed MHUA|POAI: Short-Term Debt to Capital|Callan JMB (CJMB) - Short-Term Debt to Capital|Short-Term Debt to Equity Atrion Corporation|Short-Term Debt to Capital Ratio NURO (neurometrix.com)